Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GR1501 (Xeligekimab) in Radiographic Axial Spondyloarthritis
NCT05881785Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xeligekimab in ankylosing spondylitis (AS) (3 arms), sponsored by Zhixiang Jintai. Primary endpoint: Assessment of SpondyloArthritis international Society 20 response at 16 weeks. Started Jun 2022; status: completed.
02
Drugs
xeligekimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05881785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881785.